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Abstract: Selenium is an essential micronutrient, and a low selenium concentration (<100 µg/L) is
associated with a poorer quality of life and exercise capacity, and an impaired prognosis in patients
with worsening heart failure. Measuring selenium concentrations routinely is laborious and costly,
and although its clinical utility is yet to be proven, an easy implemented model to predict selenium
status is desirable. A stepwise multivariable logistic regression analysis was performed using
routinely measured clinical factors. Low selenium was independently predicted by: older age, lower
serum albumin, higher N-terminal pro-B-type natriuretic peptide levels, worse kidney function, and
the presence of orthopnea and iron deficiency. A 10-points risk-model was developed, and a score of
≥6 points identified >80% of patients with low selenium (sensitivity of 44%, specificity of 80%). Given
that selenium and iron overlap in their physiological roles, we evaluated the shared determinants and
prognostic associates. Both deficiencies shared similar clinical characteristics, including the model
risk factors and, in addition, a low protein intake and high levels of C-reactive protein. Low selenium
was associated with a similar or worse prognosis compared to iron deficiency. In conclusion, although
it is difficult to exclude low selenium based on clinical characteristics alone, we provide a prediction
tool which identifies heart failure patients at higher risk of having a low selenium status.
Keywords: selenium; malnutrition; heart failure; albumin; iron deficiency
1. Introduction
Heart failure (HF) is a clinical syndrome resulting from impaired ventricular filling or the ejection
of blood. HF accounts for substantial morbidity and mortality, with increasing prevalence globally [1].
Various factors play a causative role in developing HF, including myocardial infarction, hypertension,
diabetes, and valvular heart diseases [1]. Moreover, in the last decade micronutrient deficiencies have
been implicated in the development and progression of HF [2]. An aberrant equilibrium of minerals
and trace elements (for example, iron, iodine, and zinc) in patients’ circulation is closely associated with
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the development and progression of HF [3,4]. Up to 50% of patients with HF suffer from some form of
malnutrition, such as micronutrient insufficiencies [5,6]. A deficiency in the trace element iron was
associated with decreased cardiomyocyte contractility and increased morbidity and mortality [7–9],
whereas treatment with intravenous iron has been shown to relieve symptoms [10–12]. Phase III clinical
trials with the aim of improving patient prognosis are currently being conducted (NCT02937454) [13].
Selenium (Se) is an essential micronutrient which has been less intensively studied though
previous studies, suggesting that very severe deficiency in humans is associated with cardiomyopathy
(Keshan disease) [3,14]. Recently, we showed that approximately 25% of patients with worsening HF
have a serum Se < 70 µg/L, and that this was associated with a poorer quality of life, poor exercise
capacity, and a worse prognosis [15]. Furthermore, a serum Se concentration of 70–100 µg/L appeared
to have similar adverse associations, suggesting that values < 100 µg/L might be considered insufficient
for the physiological requirement and thus abnormal [16,17]. The supplementation of Se is relatively
simple and safe, but its clinical utility has yet to be proven. However, since Se is not measured
routinely in clinics due to the labor intensity and subsequent high costs, identifying patients with a
low Se is challenging. Furthermore, Se and iron share several physiological functions, such as redox
homeostasis [3,9], angiogenesis [18], and immune response [3,9]. Nevertheless, the effects of the
potential shared risk factors and interactions between both deficiencies on the prognosis of HF patients
are not known.
In this study, we used the clinical predictors of a low serum Se concentration (<100 µg/L) in
patients with worsening HF to develop a model capable of predicting the presence of a low Se level.
Such a model will provide insights of the clinical factors related to Se and could improve the selection
of patients that might benefit from Se supplementation, although this needs to be evaluated in clinical
trials. In addition, we studied the levels of both Se and iron in association with the identified clinical
predictors. Finally, we investigated the associations of Se and iron with prognosis independent from
each other in established risk-models.
2. Materials and Methods
2.1. Study Population
We used data from the BIOSTAT-CHF index cohort (a systems BIOlogy Study to TAilored Treatment
in Chronic Heart Failure), which has been described previously [19,20]. In short, BIOSTAT-CHF is
a European cohort consisting originally of 2516 patients from 69 centers in 11 European countries.
The included patients had to be 18 years old or older, with symptoms of new-onset or worsening
HF. Their cardiac function has to be characterized by at least one of the following: a left ventricular
ejection fraction (LVEF) of ≤40%, a plasma B-type natriuretic peptide (BNP) of >400 pg/mL, or a plasma
N-terminal pro-B-type natriuretic peptide (NT-proBNP) of >2000 pg/mL. In addition, patients could only
be included if they were sub-optimally treated for HF at inclusion (i.e., ≤50% of angiotensin-converting
enzyme inhibitors, angiotensin receptor blockers, and/or beta-blockers). Patients with sepsis, acute
myocarditis, or monogenic cardiomyopathy were excluded. The study was conducted in consensus
with the Declaration of Helsinki. Informed consent was obtained from all the participants prior to any
study-related activities.
2.2. Laboratory Measurements and Related Definitions
Blood samples were collected during the index hospitalization or at the outpatient clinic.
Approximately 80 mL of blood plasma and serum were collected and stored at −80 ◦C. The serum
Se was measured using the validated inductively coupled plasma mass spectrometry (ICP-MS)
method, as described previously [15]. A low serum Se concentration was set at serum levels of below
100 µg/L based on previous observations in patients with worsening HF [15]. The serum NT-proBNP
concentrations were measured using an immunoassay based on electrochemiluminescence (Elecsys,
Roche Diagnostics, Mannheim, Germany). Kidney function was calculated using the Modification
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of Diet in Renal Disease (MDRD) equation. Anemia was defined according to the WHO standards
(hemoglobin level < 12 g/dL in women and <13 g/dL in men). The iron-related parameters were
measured as described previously by van der Wal et al. [9], and iron deficiency (ID) was defined as a
transferrin saturation (TSAT) < 20% [7,21]. HF with reduced ejection fraction (HFrEF) was defined as a
left ventricular ejection fraction < 40%.
2.3. Statistical Analysis
2.3.1. Baseline Characteristics
All the statistical analyses were performed using Stata v.16 SE and Weka v.3.6.15. The patients
were divided into two groups based on their Se status (low Se (<100 µg/L) vs. normal Se (≥100 µg/L)).
Variables with a normal distribution were presented as a mean (standard deviation), while continuous
variables with a non-normal distribution were presented as a median (interquartile range), and
categorical variables were presented as a count (percentage). The baseline characteristics were analyzed
using a t-test for continuous variables with a normal distribution, the Mann–Whitney U test for
continuous variables with skewed data, and the Chi-square test for categorical variables.
2.3.2. Clinical Predictors of Low Se
To identify independent predictors of low Se, a stepwise multivariable logistic regression analysis
was performed. The potential determinants that can enter this analysis had to fulfill the following
criteria: (i) a significant difference between the stratified groups in the baseline table, (ii) the potential
predictor had to be used/measured/obtained routinely in the clinical practice, and (iii) the potential
determinant should not have missing values > 15%. If two biologically similar variables fulfilled these
criteria (i.e., hemoglobin and anemia), only one variable was included in the analysis. The variables
fulfilling these criteria are summarized in Table A1. After the stepwise regression, a multivariable
logistic regression was performed on the selected variables to accurately establish their association
with Se in the entire cohort. As a sensitivity analysis, a multivariable Lasso logistic regression model
as well as a bootstrap analysis were performed, using the “Lasso” and “swboot” packages in Stata.
The multicollinearity of the final model was checked by calculating the variance inflation factor, the
values of which should not exceed a maximum of 10 [22].
2.3.3. Prediction Model
The optimal cutoff values for the independent predictors were determined using the unsupervised
discretization tool in Weka [23]. Three not necessarily equal clusters were formed per continuous
variable, the cutoff values of which were used to establish a risk-model. Two points were given to
the values that favor low Se concentration the most, 1 point to the middle values, and 0 point to the
remaining group. After determining the number of patients matching each score, the Odds Ratio’s
(OR) of each score having a low Se were calculated. The test characteristics (i.e., sensitivity, specificity)
were calculated in order to provide insights on the performance of the risk-model.
2.3.4. Comparing Determinants and Prognosis of Low Se and ID
In order to visualize the prevalence of ID in comparison to low Se with regard to the identified
predictors, restricted cubic splines (five knots for all variables) were constructed. The prevalence of
anemia was also assessed in these analyses as a reference. The influence of low Se and ID on the
outcome was further assessed using a Cox proportional hazard regression analysis. Both low Se and
ID were added together in the models to assess the independency and additionally corrected for the
BIOSTAT-CHF risk-models that predict the 2-year combined endpoint of HF hospitalizations and
mortality and the 2-year all-cause mortality alone [20].
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3. Results
3.1. Patient Characteristics
The mean Se concentration in the studied cohort of 2328 HF patients was 89.1 (24.8) µg/mL, with
1633 (70.1%) of patients having Se values < 100 µg/L. The differences between patients with a low Se
and a normal Se were largely similar to those previously reported for patients with a Se deficiency
(<70 µg/L) [15]. Patients with a low Se were significantly older (70.1 [±11.9] years vs. 66.0 [±11.8],
p < 0.001), were more likely to be female (28.0% vs. 21.6%, p < 0.001), had worse symptoms (39.6%
NYHA class III/IV vs. 30.1%, p < 0.001), were more likely to have a left ventricular ejection fraction
>40% (21.3% vs. 12.9%, p < 0.001), and had a higher prevalence of renal insufficiency (estimated
Glomerular Filtration Rate (eGFR) < 60 mL/min) (48.0% vs. 41.4%, p < 0.001). Furthermore, low Se was
associated with a pro-inflammatory profile (median IL6; 5.8 [3.2–11.4] vs. 3.9 [2.1–7.4] µg/L, p < 0.001)
and median C-reactive protein (CRP) (14,151.5 [6760.5–27,734.3] vs. 11,091.9 [4127.5–22,689.7] mg/L,
p < 0.001), as well as higher cardiac biomarkers. In addition, ID was present in 1436 (62.0%) patients,
while anemia was present in 772 (36.3%) patients (Table A2). The prevalence of both ID (66.4% vs.
51.7%, p < 0.001) and anemia (39.2% vs. 28.9%, p < 0.001) was higher in patients with low Se.
3.2. The Clinical Predictors and Diagnostic Accuracy of the Risk-Model
Older age, lower serum albumin, higher NT-proBNP levels, worse kidney function, and the
presence of orthopnea and ID were independent predictors for low Se status (Table 1, c-statistic 0.6923).
These determinants remained highly selective in the additional sensitivity analyses using bootstrapping
and Lasso penalized regression (Tables A3 and A4). No multicollinearity was detected (variance
inflation factors: 1.05–1.27). Although there were some variations between the selenium levels among
the included countries, the geographical location did not remain statistically significant as a predictor
in the stepwise multivariable logistic regression analysis (Table A5).
Table 1. Independent determinants of low selenium concentrations.
Factor Odds Ratio Standard Error z p Value 95% Confidence Interval
eGFR (Kidney Function) 1.01 0.00 2.68 0.007 1.00 1.01
Iron Deficiency 1.36 0.14 3.02 0.002 1.11 1.66
NTproBNP 1.30 0.04 8.71 <0.001 1.23 1.39
Albumin 0.97 0.01 −4.55 <0.001 0.96 0.99
Orthopnoea 1.43 0.15 3.31 0.001 1.16 1.77
Age 1.02 0.00 4.63 <0.001 1.01 1.03
Unsupervised discretization resulted in clusters with different densities per group (Table A6).
NT-proBNP values ≥ 3900 ng/L, an age of 81 years-old or older, albumin levels ≤ 24 g/L, or a kidney
function ≤ 41 mL/min/1.73 m2 qualified patients to receive two points for each variable (Figure 1A).
The percentage of patients with a low selenium concentration increases with higher scores, ranging
from 43% of the total patients who scored 0 points to 100% who scored 10 points (Figure 1B). A score
of ≥6 points identified > 80% of patients with low selenium (sensitivity of 44%, specificity of 80%).
A score ≥ 5 leads to the most balanced statistical measures, with a sensitivity of 61% and specificity of
62%, and only 1.26 HF patients are needed to be tested to identify a case of low Se status (Table 2).
In comparison, were all patients screened for low selenium concentrations, this would result in 1
positive case for every 2.4 patients.
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3.3. Prevalence of Se, Iron, and Anemia in Association with the Identified Clinical Predictors
Each pr dictor f r low Se was associated sign ficantly with ID a d anem a in restricted cubic
splines (p < 0.05). Patients aged > 65 years and/or with an albumin <± 32 g/L had a higher risk of
having any of these deficiencies (Figure 2A,B). Low Se and ID show similar associations with the
NT-proBNP levels and eGFR. Anemia is especially strongly associated with renal function; a sharp
increase in the prevalence of anemia can be observed at patients with an eGFR < 60 mL/min/1.73 m2
(Figure 2D). Restricted cubic splines were also constructed for the daily protein intake and CRP, as
it was shown to be a risk factor for ID [9]. Low Se, ID, and anemia all show a similar increasing
prevalence with a lower estimated protein intake (Figure 2E), while CRP was strongly associated with
mainly ID (Figure 2F).
3.4. Associations with Prognosis Comparing Low Serum Se Concentrations and ID
Both low Se and ID were associated with an unfavorable prognosis univariably and were also
independent from each other (Figure 3). In order to assess the associations of low Se and ID with a
prognosis independent from each other and known cardiovascular risk factors, we analyzed both
by adding them as factors in the previously established BIOSTAT models [20]. Both low Se and ID
were significantly associated with the combined 2-year endpoint of HF hospitalizations and mortality
(hazard ratio (HR) 1.23; 95% confidence interval (CI) 1.05–1.44; p = 0.009 and HR 1.26; 95% CI 1.09–1.45;
p = 0.002, respectively). Low Se remained independently associated with 2-year all-cause mortality
(HR 1.38; 95% CI 1.13–1.69; p = 0.001) when corrected for ID (Figure 3).
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Figure 2. Comparing the prevalence of low serum Se concentrations, ID, and anemia. Restricted cubic
splines of the association between the prevalence of serum selenium <100 µg/L, iron deficiency, and
anemia and (A) age, (B) albumin levels, (C) transformed NT-proBNP values, (D) kidney function
(according to the MDRD formula), (E) estimated protein intake, and (F) transformed CRP values.
The solid lines indicate estimates of the prevalence of low selenium concentrations (red), ID (green), and
anemia (blue) across continuous levels of the identified clinical determinants of low selenium, fitted
using a logistic regression analysis. The shaded areas indicate 95% confidence intervals. The p-values
indicate the significance of the whole cubic spline model for each factor.
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regression odels for the prediction of the combined outcome and all-cause mortality. (a): seru
seleniu <100 µg/L or iron deficiency as univariate predictors in different models. (b): serum seleniu
<100 µg/L and iron deficiency together in one model. (c): serum selenium <100 µg/L and iron deficiency
together in one model and corrected for the BIOSTAT-CHF risk-model, consisting of age, Heart Failure
hospitalization in the year before inclusion, the presence of edema, higher NTproBNP, lower systolic
blood pressure, hemoglobin, high- ensity lipoprotein (HDL) levels, serum sodium concentration, and
fail re to prescribe a beta-blocker. (d): serum selenium <100 µg/L and iron deficiency together in one
mo el a corrected for t e BIOSTAT-CHF mortality risk-model, consisting of age, higher blood urea
nitrogen (BUN), NT-proBNP, hemoglobin, and failure to prescribe a beta-blocker.
4. Discussion
Using an established cohort of patients with worsening HF, we used independent predictors
of low Se (<100 µg/L)—older age, lower levels of albumin, worse kidney function, higher levels of
NT-proBNP, and the presence of orthopnea and ID—to establish a prediction tool for low selenium in
HF patients. Low serum selenium concentrations were present in 1633 (70.1%) HF patients. By taking
a score of 6 or higher in this scoring system, the number of samples needed to be tested for one positive
case could be reduced from 2.4 to 1.19. With the exception of CRP, the prevalence of low Se and ID
showed similar patterns in relation to the clinical predictors. Additionally, a low Se was independent of
ID, and the previously established risk factors were associated with the primary (combined) endpoint
and mortality alone.
In contrast to what has been reported previously [24,25], smoking, alcohol, or BMI were not
significantly associated with selenium status. Although subjects from most countries had similar
selenium levels and geographical location was not independently associated with low selenium levels,
relatively high selenium levels were found in subjects from Italy and low levels were seen in subjects
from Slovenia (Table A5). Italy was the only country with mean selenium levels of above 100 µg/L,
which might be attributed to the Mediterranean diet, which contains selenium-rich components such
as fish and nuts [26].
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4.1. Using Clinical Variables to Predict Low Se
The developed a risk-model that could facilitate the efficient identification of patients at high
risk of having a low Se level—for example, in the case of screening for a clinical trial targeting Se
as an interventional therapy. With a score of 6 points or higher, approximately 80% of patients with
a serum Se < 100 µg/L could be identified. We recently showed that serum Se levels between 70
and 100 µg/L appeared to have similar adverse associations such as deficiency (<70µg/L), suggesting
that values < 100 µg/L might be considered insufficient for the physiological requirement and thus
abnormal [27,28]. This is supported by molecular evidence that shows that a serum Se of at least
100 µg/L is needed to have optimal glutathione peroxidase (GPx) and Selenoprotein P activity [29–33].
Determining the Se baseline concentrations is essential, as only those with suboptimal levels might
benefit from supplementation, although such a hypothesis needs to be evaluated in a well-designed
clinical trial. While the risk-model can help to detect approximately 84% of HF patients with low Se
with a score ≥ 6, it should be noted that ruling out low Se is challenging. Even in the population with a
score of 0, 43% of the patients had a low Se level.
4.2. Clinical Predictors of Low Se
4.2.1. Age
Age has been reported before as an important determinant of Se concentrations [25,34]. A decrease
in the serum Se levels was mainly observed in patients older than 70 years. [25,35]. Decreased
absorption capacity and impaired intestinal function with aging, as well as increased oxidative stress
and inflammation in the elderly, are suggested as underlying causes [36,37]. Dietary intake also seems
to play a relevant role, as those with a lower protein intake were more likely to have low Se status,
although it was not an independent predictor of Se status (Figure 2E).
4.2.2. NT-proBNP and Orthopnea
In a placebo controlled intervention study, Se supplementation (in combination with coenzyme
Q10) showed a reduction in the 10-year cardiovascular mortality and NT-proBNP levels in healthy
elderly, supporting the hypothesis of a causal relationship between Se and NT-proBNP [38]. Orthopnea,
a sign of congestive HF, represents the deteriorated cardiac health status.
4.2.3. Kidney Function and Albumin
Worse kidney function and lower Se status frequently occur simultaneously [39,40]. A recent
in vivo study illustrated that a Se-deficient diet led to significant increase in the urinary
protein/creatinine ratio, a reduction in the mitochondrial protein levels, increased oxidative stress
markers, as well as histological changes in kidney tissues, suggesting a causative role of Se deficiency
in inducing kidney injury [41].
Next to this, several observational patient studies showed a positive correlation between Se and
albumin levels [42,43], which was substantiated by in vivo evidence showing that Se supplementation
increased albumin concentration [44]. However, residual confounding or a reverse association (i.e.,
low albumin leads to low Se levels) cannot be excluded, as approximately 10% of the total serum Se
binds to albumin [42].
4.2.4. Iron Deficiency
ID as a determinant for low serum Se concentrations has not been reported previously. However,
several studies reported the presence of ID in Se-deficient patients [45,46]. Shared risk factors and
dietary effects are likely to play a role, although the availability of Se in the diet is more geographically
dependent on its concentration in the soil. While they are both mainly absorbed in the duodenum, it is
not clear whether there is direct or indirect physiological interaction between both elements.
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4.3. The Prevalence of Low Serum Se Concentrations, ID, and Anemia in Relation to the Determinants
Our data show that low Se and ID have important similarities in their associations with patient
characteristics. The similarity in the patterns supports the hypothesis that both elements share similar
underlying detrimental processes. We previously reported that inflammation, chronic kidney disease,
lower hemoglobin levels, and lower serum albumin levels were independent predictors for ID in HF
patients [9].
4.4. Low Serum Se Concentrations Associate with Worse Prognosis than ID
Including both ID and low Se concentration in the BIOSTAT prediction models indicated that
low Se status is independently associated with mortality in HF patients when additionally corrected
for ID (Figure 3). Clinical trials of intravenous iron supplements have shown improvements in the
symptoms and well-being of HF patients, and trials investigating the effects on morbidity and mortality
are underway. Unlike iron, selenium is readily absorbed orally. However, it should be acknowledged
that, although we showed that low Se was associated with a similar or worse prognosis compared to
ID, more evidence from well-designed clinical trials, like those performed for ID, is needed to evaluate
the potential benefits for Se supplementation in HF.
4.5. Strengths and Limitations
The BIOSTAT-CHF cohort is a large HF cohort in which comprehensive clinical and biochemical
markers were measured. Nevertheless, it should be acknowledged that it included mainly patients
with Caucasian origins. The development of a clinical tool to predict Se levels using clinical factors
remains as a challenging task, as the sensitivity of having a score 6 in our model is 44%. This could be
attributed to the high prevalence of low Se levels in this cohort, and this may indicate that determining
the Se status in patients with HF may be standardized when the clinical benefits are established
in clinical trials. Additionally, due to the observational nature of the study, establishing a causal
relationship between our results and Se concentrations is not possible. No data were currently available
on other markers of selenium-dependent pathways, nor oxidative stress. As a result, other signaling
components such as Selenoprotein P or gluthatione peroxidases were not investigated next to the
serum selenium.
5. Conclusions
In this study, we developed a prediction tool which identifies HF patients at higher risk of having
a low Se level. Yet, it remains a challenge to exclude patients with low Se levels based on clinical
characteristics alone. Low Se and ID share to large extent similar predictors. Finally, a lower Se status
is associated with similar or worse prognosis compared to, and independent of, ID.
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HF, heart failure; CI, confidence interval; CRP, C-reactive protein; GPx, glutathione peroxidase; HFrEF, heart
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Appendix A
Table A1. Selected variables that entered the analysis and their degree of missingness.
Factor Percentage
Age (years) 0 0.00
Females (%) 0 0.00
Estimated protein intake (g/day) 167 7.17
NYHA functional class 288 12.37
Orthopnoea 5 0.21
Iron deficiency 13 0.55
Atrial fibrillation 0 0.00
CRP (mg/L) 98 4.21
NTproBNP (ng/L) 58 2.49
eGFR (MDRD) (mL/min/1.73 m2) 7 0.30
Albumine (g/L) 12 0.52
Hemoglobin 200 8.59
Beta-blockers - baseline 0 0.00
Aldosteron antagonist 0 0.00
Country 0 0.00
Heart rate (b.p.m) 6 0.99
Table A2. Baseline characteristics.
Factor Level Value Se ≥ 100 µg/L Se < 100 µg/L p-Value
N 2328 695 1633
Selenium (µg/L) 89.1 (24.8) 118.5 (18.2) 76.6 (14.5) <0.001
Demographics
Age (years) 68.8 (12.0) 66.0 (11.8) 70.1 (11.9) <0.001
Females (%) 607 (26.1%) 150 (21.6%) 457 (28.0%) 0.001
BMI (kg/m2) 27.2 (24.1, 30.6) 27.7 (24.4, 30.7) 26.9 (24.0, 30.6) 0.072
Estimated protein intake (g/day) 53.4 (46.5, 62.0) 54.6 (47.3, 64.6) 52.9 (46.1, 61.1) <0.001
Ischemic etiology 1057 (46.2%) 315 (46.2%) 742 (46.2%) 0.98
LVEF (%) 30.0 (25.0, 36.0) 30.0 (25.0, 35.0) 30.0 (25.0, 38.0) 0.002
HFrEF (LVEF < 40) 1691 (81.3%) 554 (87.1%) 1137 (78.7%) <0.001
NYHA functional class Class I 214 (10.5%) 83 (13.3%) 131 (9.3%) <0.001
Class II 1077 (52.8%) 353 (56.6%) 724 (51.1%)
Class III 672 (32.9%) 174 (27.9%) 498 (35.2%)
Class IV 77 (3.8%) 14 (2.2%) 63 (4.4%)
Previous hospitalization for HF 720 (30.9%) 201 (28.9%) 519 (31.8%) 0.17
Heart rate (b.p.m) 76.0 (66.0, 90.0) 75.0 (65.0, 86.0) 77.0 (68.0, 90.0) <0.001
Systolic blood pressure (mmHg) 120.0 (110.0, 138.0) 120.0 (110.0, 135.0) 120.0 (110.0, 140.0) 0.39
Diastolic blood pressure (mmHg) 74.9 (13.1) 75.0 (12.3) 74.8 (13.5) 0.71
Peripheral oedema 1149 (59.4%) 255 (44.6%) 894 (65.6%) <0.001
Pulmonary oedema 507 (32.2%) 128 (30.7%) 379 (32.8%) 0.44
Elevated JVP No 1025 (62.9%) 393 (75.9%) 632 (56.8%) <0.001
Yes 514 (31.5%) 102 (19.7%) 412 (37.1%)
Uncertain 91 (5.6%) 23 (4.4%) 68 (6.1%)
Orthopnoea 802 (34.5%) 180 (25.9%) 622 (38.2%) <0.001
Hepatomegaly 331 (14.3%) 102 (14.7%) 229 (14.1%) 0.71
Completion of 6MWT 1462 (64.9%) 499 (73.4%) 963 (61.2%) <0.001
Result 6MWT (m) 330.0 (180.0, 429.0) 365.5 (240.0, 449.0) 310.0 (143.0, 420.0) <0.001
KCCQ (overall score) 49.0 (31.3, 66.7) 56.3 (38.5, 71.9) 44.8 (29.2, 63.5) <0.001
Smoking (none, past, current) None 853 (36.7%) 235 (33.9%) 618 (37.9%) 0.18
Past 1138 (48.9%) 354 (51.0%) 784 (48.1%)
Current 334 (14.4%) 105 (15.1%) 229 (14.0%)
Current alcohol use 644 (27.7%) 196 (28.3%) 448 (27.5%) 0.69
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Table A2. Cont.
Factor Level Value Se ≥ 100 µg/L Se < 100 µg/L p-Value
Medical history
Myocardial infarction 891 (38.3%) 258 (37.1%) 633 (38.8%) 0.46
CABG 402 (17.3%) 133 (19.1%) 269 (16.5%) 0.12
Valvular surgery 171 (7.3%) 54 (7.8%) 117 (7.2%) 0.61
PCI 512 (22.0%) 162 (23.3%) 350 (21.4%) 0.32
Atrial fibrillation 1048 (45.0%) 272 (39.1%) 776 (47.5%) <0.001
Device therapy 580 (24.9%) 190 (27.3%) 390 (23.9%) 0.078
Stroke 214 (9.2%) 53 (7.6%) 161 (9.9%) 0.088
Peripheral arterial disease 251 (10.8%) 75 (10.8%) 176 (10.8%) 0.99
Renal insufficiency (eGFR <60
mL/min) 1068 (46.0%) 287 (41.4%) 781 (48.0%) 0.003
Renal disease (history) 646 (27.7%) 167 (24.0%) 479 (29.3%) 0.009
Hypertension 1452 (62.4%) 428 (61.6%) 1024 (62.7%) 0.61
Diabetes mellitus 750 (32.2%) 222 (31.9%) 528 (32.3%) 0.85
COPD 403 (17.3%) 109 (15.7%) 294 (18.0%) 0.18
Current malignancy 87 (3.7%) 18 (2.6%) 69 (4.2%) 0.057
Laboratory





Creatinin (µmol/L) 101.0 (82.2, 129.0) 100.0 (82.1, 123.8) 101.4 (82.2, 131.6) 0.24
Urea (mmol/L) 11.3 (7.6, 18.2) 12.1 (7.8, 19.2) 11.0 (7.5, 17.8) 0.049
Proteinuria (mg/dL) 5.0 (0.0, 20.0) 5.0 (0.0, 20.0) 2.0 (0.0, 20.0) 0.68
Sodium (mmol/L) 139.2 (3.9) 139.4 (3.5) 139.1 (4.1) 0.25
Potassium (mmol/L) 4.3 (0.6) 4.3 (0.5) 4.3 (0.6) 0.95










eGFR (MDRD) (mL/min/1.73 m2) 65.0 (26.3) 67.7 (27.5) 63.9 (25.7) 0.001
IL-6 (pg/mL) 5.2 (2.8, 10.2) 3.9 (2.1, 7.4) 5.8 (3.2, 11.4) <0.001
Total bilirubin (µmol/L) 14.0 (9.9, 21.0) 13.2 (9.1, 18.8) 14.3 (10.0, 22.2) 0.001
Leucocytes (10e9/L) 8.3 (2.9) 8.3 (2.7) 8.3 (2.9) 0.95
Troponin I (µg/L) 0.0 (0.0, 0.1) 0.0 (0.0, 0.1) 0.0 (0.0, 0.1) 0.006
Troponin T (µg/L) 0.0 (0.0, 0.1) 0.0 (0.0, 0.1) 0.0 (0.0, 0.1) 0.71
Glucose (mmol/L) 6.3 (5.4, 7.9) 6.3 (5.4, 8.0) 6.2 (5.3, 7.9) 0.22
HbA1c (%) 6.3 (5.7, 7.1) 6.4 (5.8, 7.3) 6.2 (5.7, 7.0) 0.24
ASAT (U/L) 25.4 (19.0, 35.0) 25.0 (19.0, 35.0) 26.0 (20.0, 35.0) 0.35
ALAT (U/L) 25.0 (17.0, 38.0) 28.0 (20.0, 42.0) 23.0 (16.0, 36.0) <0.001
γ-GT (U/L) 55.0 (28.0, 108.5) 44.0 (26.0, 84.0) 60.0 (29.0, 118.0) <0.001
Alkaline phosphatase (µg/L) 84.0 (65.0, 118.0) 77.0 (62.0, 104.0) 88.0 (67.0, 122.0) <0.001
HDL (mmol/L) 1.1 (0.8, 1.3) 1.1 (0.9, 1.3) 1.0 (0.8, 1.3) 0.065
LDL (mmol/L) 2.6 (1.1) 2.8 (1.1) 2.5 (1.1) <0.001
Total cholesterol (mmol/L) 4.3 (1.3) 4.5 (1.4) 4.2 (1.3) <0.001
Triglycerides (mmol/L) 1.2 (0.9, 1.7) 1.3 (1.0, 1.8) 1.2 (0.9, 1.6) <0.001
TSH (mU/L) 1.8 (1.2, 3.0) 1.8 (1.1, 3.2) 1.8 (1.2, 3.0) 0.85
FT4 (pmol/L) 16.8 (7.6) 17.3 (10.6) 16.5 (5.6) 0.29
Albumine (g/L) 33.0 (27.0, 38.0) 34.0 (30.0, 40.0) 32.0 (26.5, 37.0) <0.001
Hemoglobin (g/dL) 13.2 (1.9) 13.6 (1.8) 13.0 (1.9) <0.001
Anemia 772 (36.3%) 176 (28.9%) 596 (39.2%) <0.001
Mean corpuscular volume (fL) 90.4 (8.6) 91.0 (7.8) 90.2 (8.9) 0.097
Iron deficiency 1436 (62.0%) 357 (51.7%) 1079 (66.4%) <0.001
Iron (mg/dL) 44.7 (27.9, 72.6) 55.9 (39.1, 78.2) 44.7 (27.9, 67.0) <0.001
Ferritin (µg/L) 101.0 (50.0, 191.5) 126.0 (62.5, 208.0) 93.0 (46.0, 185.0) <0.001
Transferrin (mg/dL) 206.0 (69.7) 211.9 (67.9) 203.5 (70.4) 0.008
Transferrin saturation (%) 17.1 (10.9, 24.9) 19.9 (13.3, 27.2) 15.9 (9.9, 23.5) <0.001
Hepcidin (nmol/L) 6.3 (2.2, 16.5) 7.5 (3.1, 17.3) 5.7 (1.8, 15.9) <0.001
sTfR (mg/L) 1.8 (1.0) 1.5 (0.8) 1.9 (1.1) <0.001
Medication
Betablocker - baseline 1941 (83.4%) 597 (85.9%) 1344 (82.3%) 0.033
ACE/ARB - baseline 1685 (72.4%) 522 (75.1%) 1163 (71.2%) 0.055
Antiplatelets 1208 (51.9%) 363 (52.2%) 845 (51.7%) 0.83
P2Y12V2 359 (15.4%) 101 (14.5%) 258 (15.8%) 0.44
Diuretics 2326 (99.9%) 694 (99.9%) 1632 (99.9%) 0.53
Loop Diuretics 2317 (99.5%) 690 (99.3%) 1627 (99.6%) 0.26
Oral anti-diabetics 469 (62.5%) 133 (59.9%) 336 (63.6%) 0.34
Insuline use 301 (40.1%) 93 (41.9%) 208 (39.4%) 0.52
Proton pump inhibitor 815 (35.0%) 237 (34.1%) 578 (35.4%) 0.55
Acenocoumarol 896 (38.5%) 258 (37.1%) 638 (39.1%) 0.38
Aldosteron antagonist 1241 (53.3%) 398 (57.3%) 843 (51.6%) 0.013
Spironolactone 855 (36.7%) 250 (36.0%) 605 (37.0%) 0.62
LVEF, Left Ventricular Ejection Fraction; HF, Heart Failure; JVP, Jugular Venous Pressure; CABG, Coronary Artery
Bypass Grafting; PCI, Percutaneous coronary intervention; COPD, Chronic Obstructive Pulmanory Disease.
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Table A3. Results of the bootstrapping analysis.
N. of Repetion
Age (years) 856
NTproBNP (per doubling) 1000




Table A4. Results of LASSO penalized regression.
Predictor # Penalized Odds Ratios
NTproBNP 1.32
Albumin 0.98




# Variables are ordered based on their absolute values of their coefficients, starting from the largest. LASSO, Least
Absolute Shrinkage and Selection Operator.
Table A5. Selenium values based on geographical location.
Country Number of IncludedPatients Mean Selenium
Percentage of
Patients < 100 µg/L
the Netherlands 386 86.00 76.68
France 243 80.70 80.66
Germancy 87 90.69 67.82
Serbia 382 91.23 66.49
Slovenia 43 66.83 97.67
Greece 285 90.87 68.42
Italy 297 115.48 27.61
Norway 108 79.16 86.11
Sweden 97 79.49 84.54
Poland 239 79.33 87.45
United Kingdom 161 84.42 77.64
Table A6. Number of patients with selenium <100 µg/L per cluster per variable.
Factor 0 Point 1 Point 2 Points Total Number of Patients
NTproBNP 555 352 685 1592
eGFR Kidney Function 343 977 307 1627
Albumin 264 1050 310 1624
Age 374 972 287 1633
Iron deficiency 545 1079 NA 1624
Orthopnoea 1006 622 NA 1628
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45. Gürgöze, M.K.; Ölçücü, A.; Aygün, A.D.; Taşkin, E.; Kiliç, M. Serum and hair levels of zinc, selenium, iron,
and copper in children with iron-deficiency anemia. Biol. Trace Elem. Res. 2006, 111, 23–29. [CrossRef]
46. Van Nhien, N.; Khan, N.C.; Yabutani, T.; Ninh, N.X.; Kassu, A.; Huong, B.T.M.; Do, T.T.; Motonaka, J.; Ota, F.
Serum levels of trace elements and iron-deficiency anemia in adult Vietnamese. Biol. Trace Elem. Res. 2006,
111, 1–9. [CrossRef]
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
